References
- Akram M, Iqbal M, Daniyal M, et al. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):1–23.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
- DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495–1506.
- Dass SA, Tan KL, Selva Rajan R, et al. Triple negative breast cancer: a review of present and future diagnostic modalities. Medicina. 2021;57(1):62.
- Gonzalez L, Mortimer J, Kruper L. De-escalation of systemic therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative breast cancer. Curr Breast Cancer Rep. 2021;13(3):151–156.
- Yao H, He G, Yan S, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–1924.
- Cancer Treatment Centers of America. Breast cancer molecular types; 2022 [accessed 2022 Oct]. Available from: https://www.cancercenter.com/cancer-types/breast-cancer/types/breast-cancer-molecular-types
- European Commission. Cancer in Europe: 5 things the data tells us; 2022 [accessed 2022 Jan]. Available from: https://joint-research-centre.ec.europa.eu/jrc-news/cancer-europe-5-things-data-tells-us-2022-01-13_en
- Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–347.
- Santucci C, Patel L, Malvezzi M, et al. Persisting cancer mortality gap between Western and Eastern Europe. Eur J Cancer. 2022;165:1–12.
- La Vecchia C, Conte P. Cancer control in Central and Eastern Europe. Oncologist. 2016;21(10):1161–1162.
- Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, et al. Cancer epidemiology in Central, South and Eastern European countries. Croat Med J. 2011;52(4):478–487.
- Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–1174.
- Inotai A, Abonyi-Tóth Z, Rokszin G, et al. Prognosis, cost, and occurrence of colorectal, lung, breast, and prostate cancer in Hungary. Value Health Reg Issues. 2015;7:1–8.
- Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer‐related mortality in Europe. Int J Cancer. 2015;136(4):E136–E145.
- European Commission. Europe’s Beating cancer plan. Brussels: European Commission; 2021.
- Bencina G, Chami N, Hughes R, et al. Lost productivity due to head and neck cancer mortality in Hungary, Poland, and Romania. J Cancer Policy. 2022;34:100366.
- Eurostat. Causes of death - deaths by country of residence and occurrence mortality estimates (2010, 2015 and 2019). 2021 [accessed 2021 Oct] Available from: https://ec.europa.eu/eurostat/web/health/data/database
- The World Bank. Life expectancy at birth, female (years). 2021 [accessed 2021 Oct] Available from: https://data.worldbank.org/indicator/SP.DYN.LE00.FE.IN
- The World Bank. Life expectancy at birth, male (years). 2021 [accessed 2021 Oct] Available from: https://data.worldbank.org/indicator/SP.DYN.LE00.MA.IN
- Eurostat. Mean annual earnings by sex, age and economic activity; 2018. Available from: https://ec.europa.eu/eurostat/databrowser/view/EARN_SES18_27__custom_1501377/default/table?lang=en
- Eurostat. Minimum wages. 2015 [accessed 2021 Oct]. Available from: https://ec.europa.eu/eurostat/databrowser/view/tps00155/default/table?lang=en
- The World Bank. Labor force participation rate, national estimate. 2019 [accessed 2021 Oct]. Available from: https://data.worldbank.org/indicator/SL.TLF.CACT.NE.ZS
- van Walle L, Vandeven J, Colpaert C, et al. Incidence of breast cancer subtypes in Belgium: a population-based study. Belg J Med Oncol. 2020;14(6):263–273.
- Eurostat. Unemployment rate; 2021 [accessed 2021 Oct]. Available from: https://ec.europa.eu/eurostat/databrowser/view/tepsr_wc170/default/table?lang=en
- Eurostat. Gross domestic product at market prices; 2017 [accessed 2021 Oct]. Available from: https://ec.europa.eu/eurostat/web/products-datasets/-/tec00001
- Eurostat. Mean annual earnings by sex, age and economic activity; 2018 [accessed 2021 Oct]. Available from: https://ec.europa.eu/eurostat/databrowser/view/EARN_SES18_27__custom_1501377/default/table?lang=en
- World Bank. Population, total; 2019 [accessed 2022 Jul]. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL
- Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–49.
- Tripathy D, Curteis T, Hurvitz S, et al. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer. Ther Adv Med Oncol. 2022;14:17588359221081203. 17588359221081203.
- Trogdon JG, Liu X, Reeder-Hayes KE, et al. Productivity costs associated with metastatic breast cancer in younger, midlife, and older women. Cancer. 2020;126(18):4118–4125.
- Shah TA, Guraya SS. Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct. 2017;5(2):59–69.
- Blanks RG, Moss SM, McGahan CE, et al. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2000;321(7262):665–669.
- Thornton J. Targeted breast screening could reduce overdiagnosis and be more cost effective, study finds. BMJ. 2018;362:k3009.
- Tong CW, Wu M, Cho WC, et al. Recent advances in the treatment of breast cancer. Front Oncol. 2018;8:227.
- Wojtyla C, Bertuccio P, Wojtyla A, et al. European trends in breast cancer mortality, 1980–2017 and predictions to 2025. Eur J Cancer. 2021;152:4–17.
- Trimboli RM, Giorgi Rossi P, Battisti NML, et al. Do we still need breast cancer screening in the era of targeted therapies and precision medicine? Insights Imaging. 2020;11(1):1–10.
- Breastcancer.org Adding Keytruda to chemotherapy improves overall survival in metastatic, strongly PD-L1-positive triple-negative breast cancer. 2021.
- Burguin A, Diorio C, Durocher F. Breast Cancer treatments: updates and new challenges. JPM. 2021;11(8):808.
- Anderson WF, Jatoi I, Tse J, et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–239.
- Schneider PP, Ramaekers BL, Pouwels X, et al. Direct medical costs of advanced breast cancer treatment: a real-world study in the southeast of the Netherlands. Value Health. 2021;24(5):668–675.
- Blinder V, Eberle C, Patil S, et al. Women with breast cancer who work for accommodating employers more likely to retain jobs after treatment. Health Aff. 2017;36(2):274–281.
- Bradley CJ. Economic recovery: a measure of the quality of cancer treatment and survivorship? Cancer Am Cancer Soc. 2015;121(24):4282–4285.
- Bradley CJ, Neumark D, Luo Z, et al. Employment-contingent health insurance, illness, and labor supply of women: evidence from married women with breast cancer. Health Econ. 2007;16(7):719–737.
- Drolet M, Maunsell E, Mondor M, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ. 2005;173(7):765–771.
- Łyszczarz B, Nojszewska E. Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014. BMC Cancer. 2017;17(1):1–13.
- Wan Y, Gao X, Mehta S, et al. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013;16(10):1169–1178.